Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.
作者： P J Goodwin , R Feld , W K Evans , J Pater
DOI: 10.1200/JCO.1988.6.10.1537
关键词:
摘要: An economic evaluation of a randomized trial cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and vincristine alone or alternating with etoposide (VP-16) cisplatin in extensive small-cell lung cancer (SCLC) was undertaken. A survival benefit 1.6 months favor chemotherapy associated an additional cost $450 (1984 Canadian dollars) per patient. This translated to $3,370 year life gained. Sensitivity analyses demonstrated that the cost-effectiveness (CEA) greatest when treatment given on outpatient basis. The results were sensitive hospitalization rates, but even most unfavorable revealed CEA be comparable treatments common nonmalignant diseases. It is concluded for SCLC favorable compared accepted be...
sci-hub.se 参考文章(16)
Peter R. Carroll, Richard D. Williams, Mark J. Kim, Skaidrite Dombrovskis, Mitomycin C Reused: An in Vitro Cost-Effectiveness Study Journal of Urology. ,vol. 132, pp. 583- 586 ,(1984) , 10.1016/S0022-5347(17)49752-7
Michael F Drummond, Mark J Sculpher, Karl Claxton, Greg L Stoddart, George W Torrance, Methods for the Economic Evaluation of Health Care Programmes ,(1987)
R. J. Labelle, M. F. Drummond, M. Levine, Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin Canadian Medical Association Journal. ,vol. 133, pp. 977- 987 ,(1985) , 10.1007/978-3-642-69939-9_82
Milton C. Weinstein, Economic assessments of medical practices and technologies. Medical Decision Making. ,vol. 1, pp. 309- 330 ,(1981) , 10.1177/0272989X8100100403
Peter S. Houts, Allan Lipton, Harold A. Harvey, Barbara Martin, Mary A. Simmonds, Richard H. Dixon, Santo Longo, Thomas Andrews, Robert A. Gordon, John Meloy, Salee L. Hoffman, Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer. ,vol. 53, pp. 2388- 2392 ,(1984) , 10.1002/1097-0142(19840601)53:11<2388::AID-CNCR2820531103>3.0.CO;2-A
Sonja I. Sandberg, Benjamin A. Barnes, Milton C. Weinstein, Peter Braun, Elective hysterectomy: benefits risks and costs. Medical Care. ,vol. 23, pp. 1067- 1085 ,(1985) , 10.1097/00005650-198509000-00005
Michael H Boyle, George W Torrance, John C Sinclair, Sargent P Horwood, None, Economic Evaluation of Neonatal Intensive Care of Very-Low-Birth-Weight Infants New England Journal of Medicine. ,vol. 308, pp. 1330- 1337 ,(1983) , 10.1056/NEJM198306023082206
GarethJ.G. Rees, Cost-effectiveness in oncology. The Lancet. ,vol. 326, pp. 1405- 1408 ,(1985) , 10.1016/S0140-6736(85)92568-1
H.E.M. Kay, S.D. Lawler, R.L. Powles, H.M. Clink, COST OF BONE-MARROW TRANSPLANTS IN ACUTE MYELOID LEUKÆMIA The Lancet. ,vol. 315, pp. 1067- 1069 ,(1980) , 10.1016/S0140-6736(80)91508-1
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014